S050 The 2026 Debates: Controversies in Dermatology
DESCRIPTION
Evidence-based medicine is the conscientious and judicious use of the strongest current data in making decisions on how we care for our patients. Advances in technology, development of new therapies, and acquisition of new data challenge our best practices and may at the same time stimulate controversy. This session is designed for interactive discussion and critical thinking regarding some of the emerging issues that we are actively encountering in this current day.
LEARNING OBJECTIVES
Critically evaluate key issues and challenges in deploying molecular testing for the determination of melanoma risk and outcomes.
Define and recognize the current opportunities and challenges with developing and using Artificial Intelligence applications in dermatology.
Critically evaluate the key issues and challenges associated with melanoma (over)diagnosis and skin cancer screening.
SCHEDULE
9:00 AM
Introduction
Kenneth Y. Tsai, MD, PhD, FAAD
9:05 AM
Brave New Worlds: Embracing AI & Balancing Risks
Yevgeniy Semenov, MD, MS, FAAD, Shannon Wongvibulsin, MD, PhD
10:05 AM
How to Address The Dilemma of Melanoma Overdiagnosis
Ata Moshiri, MD, MPH, FAAD, David Polsky, MD, PhD, FAAD
11:05 AM
The Utility of Gene Expression Profiling in Skin Cancer
Emily Y. Chu, MD, PhD, FAAD, Sairekha Ravichandran, MD, FAAD
DIRECTOR
Kenneth Y. Tsai, MD, PhD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Ata Moshiri, MD, MPH, FAAD
David Polsky, MD, PhD, FAAD
Sairekha Ravichandran, MD, FAAD
Yevgeniy Semenov, MD, MS, FAAD
Shannon Wongvibulsin, MD, PhD
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Ata Moshiri, MD, MPH, FAAD
No financial relationships exist with ineligible companies.
David Polsky, MD, PhD, FAAD
BMS – Independent Contractor(Grants/Research Funding); Medscape – Speaker(Honoraria); MoleSafe, Inc. – Other(Fees); Novartis – Independent Contractor(Grants/Research Funding); Viela Bio – Advisory Board(Stock);
Sairekha Ravichandran, MD, FAAD
No financial relationships exist with ineligible companies.
Yevgeniy Semenov, MD, MS, FAAD
Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);
Kenneth Y. Tsai, MD, PhD, FAAD
3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); Ankyra Therapeutics – Independent Contractor(Grants/Research Funding); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); Regeneron Pharmaceuticals Inc – Advisory Board(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);
Shannon Wongvibulsin, MD, PhD
Sanofi/Regeneron – Advisory Board(Honoraria); VisualDx – Consultant (1099 relationship)(Honoraria);